Find Lamivudine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 134678-17-4, Epivir, Zeffix, Heptovir, Epivir-hbv, 136891-12-8
Molecular Formula
C8H11N3O3S
Molecular Weight
229.26  g/mol
InChI Key
JTEGQNOMFQHVDC-NKWVEPMBSA-N
FDA UNII
2T8Q726O95

Lamivudine
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Lamivudine is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of lamivudine is as a Nucleoside Reverse Transcriptase Inhibitor.
1 2D Structure

Lamivudine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
2.1.2 InChI
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
2.1.3 InChI Key
JTEGQNOMFQHVDC-NKWVEPMBSA-N
2.1.4 Canonical SMILES
C1C(OC(S1)CO)N2C=CC(=NC2=O)N
2.1.5 Isomeric SMILES
C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
2.2 Other Identifiers
2.2.1 UNII
2T8Q726O95
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2',3' Dideoxy 3' Thiacytidine

2. 2',3'-dideoxy-3'-thiacytidine

3. 2(1h)-pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2r-cis)-

4. 3tc Lamivudine

5. Bch 189

6. Bch-189

7. Bch189

8. Epivir

9. Gr 109714x

10. Gr-109714x

11. Gr109714x

12. Lamivudine, (+)-cis-

13. Lamivudine, (+-)-trans-

14. Lamivudine, (2s-cis)-isomer

15. Lamivudine, 3tc

2.3.2 Depositor-Supplied Synonyms

1. 134678-17-4

2. Epivir

3. Zeffix

4. Heptovir

5. Epivir-hbv

6. 136891-12-8

7. 3tc

8. Bch-189

9. Heptodin

10. 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one

11. (-)-2'-deoxy-3'-thiacytidine

12. Virolam

13. Gr-109714x

14. 3'-thia-2',3'-dideoxycytidine

15. Gr109714x

16. (-)-bch-189

17. Beta-l-2',3'-dideoxy-3'-thiacytidine

18. Beta-l-3'-thia-2',3'-dideoxycytidine

19. 2',3'-dideoxy-3'-thiacytidine

20. Gr 109714x

21. Lamivudine Teva

22. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one

23. (-)ngpb-21

24. Bch 189, (-)-

25. (-)-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine

26. 4-amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one

27. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one

28. Hepitec

29. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1h)-one

30. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone

31. Chebi:63577

32. (-)-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

33. 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone

34. 2(1h)-pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2r-cis)-

35. 2t8q726o95

36. Nsc-760061

37. Heptivir

38. Lamivir

39. Zefix

40. Bch 189

41. Lamivudine [usan:ban:inn]

42. (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine

43. 2(1h)-pyrimidinone, 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-

44. 2(1h)-pyrimidinone, 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-

45. Epivir(tm)

46. Hha & Lamivudine

47. Lamivudine & Gna

48. Smr000466319

49. Epivir (tn)

50. (-)-bch 189

51. Dthc

52. Chembl141

53. Hsdb 7155

54. Drg-0126

55. 3tc And Nv-01

56. (-)-sddc

57. Lamivudeine

58. Lamivudinum

59. Lamivudine (jan/usp/inn)

60. 3tc & Gna

61. 3tc & Sst

62. Hha & 3tc

63. (+/-)-sddc

64. Ccris 9274

65. Nsc620753

66. Unii-2t8q726o95

67. Bch-790

68. Lamivudine [usan:usp:inn:ban]

69. Rac-cis-lamivudine

70. Ncgc00159341-04

71. Lamivudine- Bio-x

72. Gg-714

73. Mfcd00869739

74. Lamivudine (epivir)

75. Cpd000466319

76. Lamivudine [mi]

77. (+/-)-3tc

78. (+/-)-bch-189

79. Lamivudine [inn]

80. Lamivudine [jan]

81. Lamivudine [hsdb]

82. Lamivudine [usan]

83. Lamivudine [vandf]

84. Lamivudine [mart.]

85. Lamivudine [usp-rs]

86. Lamivudine [who-dd]

87. Lamivudine [who-ip]

88. Mls000759424

89. Mls001424097

90. Mls006011910

91. Bidd:gt0033

92. Lamivudine [ema Epar]

93. Schembl109675

94. Amy384

95. Dtxsid7023194

96. Lamivudine [ep Impurity]

97. Lamivudine [orange Book]

98. Zinc12346

99. Lamivudine [ep Monograph]

100. Kivexa Component Lamivudine

101. Hms2051d21

102. Hms3259f08

103. Hms3713c16

104. Lamivudine [usp Monograph]

105. Epzicom Component Lamivudine

106. Lamivudinum [who-ip Latin]

107. Temixys Component Lamivudine

108. Triumeq Component Lamivudine

109. Combivir Component Lamivudine

110. Hy-b0250

111. Lamivudine Teva Pharma B.v.

112. Trizivir Component Lamivudine

113. Bbl033871

114. Bdbm50366817

115. Delstrigo Component Lamivudine

116. Mfcd00870542

117. S1706

118. Stk801940

119. Lamivudine & Tnf-alpha & Ifn-gamma

120. Telura Component Of Lamivudine

121. Akos005622556

122. Akos015854841

123. Lamivudine Component Of Epzicom

124. Lamivudine Component Of Temixys

125. Lamivudine Component Of Triumeq

126. Lamivudine, >=98% (hplc), Powder

127. (-)-bch189

128. Ac-1416

129. Ccg-100984

130. Db00709

131. Ks-1073

132. Lamivudine Component Of Combivir

133. Lamivudine Component Of Dutrebis

134. Lamivudine Component Of Trizivir

135. Nc00234

136. Nc00705

137. Nsc 760061

138. Lamivudine Component Of Delstrigo

139. Ncgc00159341-05

140. Ncgc00159341-18

141. Ncgc00159341-20

142. Bl164607

143. Emtricitabine Impurity C [who-ip]

144. L0217

145. Rac-cis-lamivudine ((2rs,5sr)-lamivudine)

146. Sw197614-3

147. C07065

148. D00353

149. P17147

150. Ab00639995-06

151. Ab00639995-08

152. Ab00639995_09

153. Lamivudeine 100 Microg/ml In Acetonitrile:water

154. 678l174

155. Q422631

156. Sr-01000759420

157. J-700183

158. Q-201275

159. Sr-01000759420-5

160. Lamivudine/zidovudine Teva Component Lamivudine

161. Lamivudine Component Of Lamivudine/zidovudine Teva

162. Lamivudine, British Pharmacopoeia (bp) Reference Standard

163. Lamivudine, European Pharmacopoeia (ep) Reference Standard

164. (2r,5s)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

165. .beta.-l-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-saiko-to

166. Lamivudine, United States Pharmacopeia (usp) Reference Standard

167. (+/-) (cis)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

168. (-)-l-2',3'-dideoxy-3'-thiacytidine; Lamivudine; Epivir

169. Lamivudine, 1.0 Mg/ml In Methanol, Certified Reference Material

170. Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material

171. (+/-)-(cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one

172. 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (cis)

173. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1h)-pyrimidin-2-one

174. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-(1h)-pyrimidin-2-one

175. Cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1h)-pyrimidinone

176. Lamivudine For System Suitability 1, European Pharmacopoeia (ep) Reference Standard

177. Lamivudine For System Suitability 2, European Pharmacopoeia (ep) Reference Standard

178. 1117764-41-6

179. 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2r,5s) & Galanthus Nivalis Agglutinin (gna)

180. 2(1h)-pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2r,5s) & Hippeastrum Hybrid Agglutinin( Hha)

181. 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one [who-ip]

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 229.26 g/mol
Molecular Formula C8H11N3O3S
XLogP3-0.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass229.05211239 g/mol
Monoisotopic Mass229.05211239 g/mol
Topological Polar Surface Area113 Ų
Heavy Atom Count15
Formal Charge0
Complexity331
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameEpivir
Drug LabelEPIVIR-HBV is a brand name for lamivudine, a synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Lamivudine was initially developed for the treatment of HIV infection as EPIVIR. Please see the complete prescribing inf...
Active IngredientLamivudine
Dosage FormTablet; Solution
RouteOral
Strength300mg; 150mg; 10mg/ml
Market StatusPrescription
CompanyViiv Hlthcare

2 of 6  
Drug NameEpivir-hbv
PubMed HealthLamivudine (By mouth)
Drug ClassesAntiretroviral Agent, Antiviral
Drug LabelEPIVIR-HBV is a synthetic nucleoside analogue with activity against HBV. The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidi...
Active IngredientLamivudine
Dosage FormTablet; Solution
RouteOral
Strength5mg/ml; 100mg
Market StatusPrescription
CompanyGlaxosmithkline

3 of 6  
Drug NameLamivudine
PubMed HealthLamivudine (By mouth)
Drug ClassesAntiretroviral Agent, Antiviral
Drug LabelEPIVIR-HBV is a brand name for lamivudine, a synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Lamivudine was initially developed for the treatment of HIV infection as EPIVIR. Please see the complete prescribing inf...
Active IngredientLamivudine
Dosage FormTablet; Solution
Routeoral; Oral
Strength150mg; 10mg/ml; 300mg; 100mg
Market StatusTentative Approval; Prescription
CompanyRanbaxy; Hetero Labs Ltd V; Macleods Pharma; Apotex; Aurobindo; Hetero Labs Ltd Iii; Alkem Labs; Aurobindo Pharma; Invagen Pharms; Cipla; Matrix Labs; Teva Pharms; Strides Arcolab; Micro Labs

4 of 6  
Drug NameEpivir
Drug LabelEPIVIR-HBV is a brand name for lamivudine, a synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Lamivudine was initially developed for the treatment of HIV infection as EPIVIR. Please see the complete prescribing inf...
Active IngredientLamivudine
Dosage FormTablet; Solution
RouteOral
Strength300mg; 150mg; 10mg/ml
Market StatusPrescription
CompanyViiv Hlthcare

5 of 6  
Drug NameEpivir-hbv
PubMed HealthLamivudine (By mouth)
Drug ClassesAntiretroviral Agent, Antiviral
Drug LabelEPIVIR-HBV is a synthetic nucleoside analogue with activity against HBV. The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidi...
Active IngredientLamivudine
Dosage FormTablet; Solution
RouteOral
Strength5mg/ml; 100mg
Market StatusPrescription
CompanyGlaxosmithkline

6 of 6  
Drug NameLamivudine
PubMed HealthLamivudine (By mouth)
Drug ClassesAntiretroviral Agent, Antiviral
Drug LabelEPIVIR-HBV is a brand name for lamivudine, a synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Lamivudine was initially developed for the treatment of HIV infection as EPIVIR. Please see the complete prescribing inf...
Active IngredientLamivudine
Dosage FormTablet; Solution
Routeoral; Oral
Strength150mg; 10mg/ml; 300mg; 100mg
Market StatusTentative Approval; Prescription
CompanyRanbaxy; Hetero Labs Ltd V; Macleods Pharma; Apotex; Aurobindo; Hetero Labs Ltd Iii; Alkem Labs; Aurobindo Pharma; Invagen Pharms; Cipla; Matrix Labs; Teva Pharms; Strides Arcolab; Micro Labs

4.2 Therapeutic Uses

Lamivudine is indicated in the treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation. This use is based on 1-year histologic and serologic responses in patients with compensated chronic hepatitis B. /Included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1646


Lamivudine is indicated, in combination with zidovudine or other antiretroviral agents, in the treatment of HIV infection or AIDS when therapy is warranted based on clinical and/or immunological evidence of disease progression. /Included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1646


Lamivudine may be used prophylactically in health care workers at risk of acquiring HIV infection after occupational exposure to the virus. It is being used in combination with zidovudine and, in some cases, a protease inhibitor. /NOT included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1646


The safety, pharmacokinetics, and antiretroviral activity of lamivudine alone and in combination with zidovudine was studied in pregnant women infected with human immunodeficiency virus type 1 (HIV-1) and their neonates. Women received the drugs orally from week 38 of pregnancy to 1 week after delivery. Neonate therapy began 12 h after delivery and continued for 1 week. Both treatment regimens were well-tolerated in women and newborns. Lamivudine and zidovudine pharmacokinetics in pregnant women were similar to those in nonpregnant adults. Lamivudine and zidovudine freely crossed the placenta and were secreted in breast milk. Neonatal lamivudine clearance was about half that in pediatric patients; zidovudine clearance was consistent with previous reports. HIV-1 RNA could be quantified in 17 of the 20 women. At the onset of labor/delivery, mean virus load had decreased by approximately 1.5 log10 copies/mL in both treatment cohorts. Although not definitive for HIV-1 infection status, all neonates had HIV-1 RNA levels below the limit of quantification at birth and at ages 1 and 2 weeks.

PMID:9780252 Moodley J et al; J Infect Dis 178 (5): 1327-33 (1998)


4.3 Drug Warning

Safety and efficacy of lamivudine in the treatment of chronic hepatitis B have not been established in patients with decompensated liver disease or organ transplants; pediatric patients; or patients dually infected with hepatitis B and hepatitis C, hepatitis delta, or HIV; or for a treatment period greater than 1 year.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 23rd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2003. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1646


Although lamivudine generally is well tolerated, serious adverse effects such as peripheral neuropathy, pancreatitis, and lactic acidosis and severe hepatomegaly with steatosis have been reported. Adverse GI effects are the most common adverse effects in patients receiving lamivudine alone or in conjunction with zidovudine. Information on adverse effects of lamivudine has been obtained from clinical studies in HIV-infected adults who received the drug in conjunction with other antiretroviral agents ... . In addition, information on adverse effects of lamivudine in patients with compensated chronic hepatitis B virus (HBV) infection has been obtained from 3 placebo-controlled studies where the drug was used alone for up to 68 weeks.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 668


Peripheral neuropathy, the major dose-limiting toxicity associated with zalcitabine therapy, has been reported in adults receiving lamivudine, but has rarely resulted in interruption or discontinuance of therapy. In clinical studies... in HIV-infected adults receiving lamivudine in conjunction with zidovudine, neuropathy was reported in 12% of the patients. Paresthesia, weakness, and peripheral neuropathy have been reported in patients receiving lamivudine during postmarketing surveillance. ... In clinical studies in adults who received lamivudine for the treatment of chronic /hepatitis B virus/ (HBV) infection, malaise, fatigue, and headache were reported in 24, 24, and 21% of patients, respectively.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 668


In HIV-infected adults receiving lamivudine in conjunction with zidovudine, headache, malaise, fatigue, insomnia and other sleep disorders, dizziness, and depressive disorders were reported in 35, 27, 27, 11, 10, and 9%, respectively.

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 668


For more Drug Warnings (Complete) data for LAMIVUDINE (20 total), please visit the HSDB record page.


4.4 Drug Indication

For the treatment of HIV infection and chronic hepatitis B (HBV).


FDA Label


Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.


Lamivudine Teva Pharma B. V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.


Zeffix is indicated for the treatment of chronic hepatitis B in adults with:

- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;

- decompensated liver disease in combination with a second agent without cross-resistance to lamivudine.


Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:

- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5. 1).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV) to disrupt viral DNA synthesis. When phosphorylated, lamivudine can form active metabolites that compete for incorporation into viral DNA. Via DNA incorporation, lamivudine metabolites competitively inhibit the activity of the HIV reverse transcriptase enzyme and act as a chain terminator of DNA synthesis. Due to the lack of a 3'-OH group, incorporated nucleoside analogues prevent the formation of a 5' to 3' phosphodiester linkage that is essential for DNA chain elongation.


5.2 MeSH Pharmacological Classification

Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)


Reverse Transcriptase Inhibitors

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
LAMIVUDINE
5.3.2 FDA UNII
2T8Q726O95
5.3.3 Pharmacological Classes
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Nucleoside Analog [EXT]; Nucleoside Reverse Transcriptase Inhibitors [MoA]; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
5.4 ATC Code

J05AF05


J05AF05


J05AF05


J05AF05


J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors

J05AF05 - Lamivudine


5.5 Absorption, Distribution and Excretion

Absorption

Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in 12 adult patients was 86% 16% (mean SD) for the 150-mg tablet and 87% 13% for the oral solution. The peak serum lamivudine concentration (Cmax) was 1.5 0.5 mcg/mL when an oral dose of 2 mg/kg twice a day was given to HIV-1 patients. When given with food, absorption is slower, compared to the fasted state.


Route of Elimination

The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. 5.2% 1.4% (mean SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Lamivudine is excreted in human breast milk and into the milk of lactating rats.


Volume of Distribution

Apparent volume of distribution, IV administration = 1.3 0.4 L/kg. Volume of distribution was independent of dose and did not correlate with body weight.


Clearance

Renal clearance = 199.7 56.9 mL/min [300 mg oral dose, healthy subjects]

Renal clearance = 280.4 75.2 mL/min [single IV dose, HIV-1-infected patients]

Total clearance = 398.5 69.1 mL/min [HIV-1-infected patients]


Lamivudine crosses the placenta and has been detected in the fetal circulation.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1359


Lamivudine has high oral bioavailability with or without food and reaches peak plasma levels within approximately 1 hour.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1359


5.6 Metabolism/Metabolites

Metabolism of lamivudine is a minor route of elimination. In man, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. This biotransformation is catalyzed by sulfotransferases.


5.7 Biological Half-Life

5 to 7 hours (healthy or HBV-infected patients)


5.8 Mechanism of Action

Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.


Lamivudine enters cells by passive diffusion and is phosphorylated to its active metabolite, lamivudine triphosphate. Lamivudine triphosphate competes with deoxycytidine triphosphate for binding to reverse transcriptase, and incorporation into DNA results in chain termination. Lamivudine has very low affinity for human alpha and omega DNA polymerases, moderate affinity for beta DNA polymerase, and higher affinity for gamma DNA polymerase.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1358


API SUPPLIERS

read-more
read-more

01

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

02

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU, MX arrow-down AUDIT
HRV Global Life Sciences

03

Emnar Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Emnar Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

04

Lantech Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Lantech Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

LONZEAL PHARMACEUTICALS CO LTD

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

LONZEAL PHARMACEUTICALS CO LTD

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF arrow-down VMF Others AUDIT arrow-down
blank

06

Styrax

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Styrax

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Viyash Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Viyash Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

08

Shijiazhuang Lonzeal Pharmac.Co. l...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Shijiazhuang Lonzeal Pharmac.Co. l...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF Inactive-api CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

SIBRA PHARMACEUTICALS LTD

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

SIBRA PHARMACEUTICALS LTD

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Anhui Biochem Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Anhui Biochem Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R1-CEP 2012-362 - Rev 00

Status : Valid

Issue Date : 2021-09-14

Type : Chemical

Substance Number : 2217

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : CEP 2009-238 - Rev 01

Status : Valid

Issue Date : 2024-01-12

Type : Chemical

Substance Number : 2217

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R1-CEP 2008-160 - Rev 02

Status : Valid

Issue Date : 2017-08-10

Type : Chemical

Substance Number : 2217

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : CEP 2013-168 - Rev 01

Status : Valid

Issue Date : 2024-05-02

Type : Chemical

Substance Number : 2217

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R0-CEP 2019-082 - Rev 01

Status : Valid

Issue Date : 2023-03-20

Type : Chemical

Substance Number : 2217

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R1-CEP 2016-045 - Rev 01

Status : Valid

Issue Date : 2023-01-24

Type : Chemical

Substance Number : 2217

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : CEP 2015-272 - Rev 01

Status : Valid

Issue Date : 2024-06-17

Type : Chemical

Substance Number : 2217

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R0-CEP 2023-119 - Rev 00

Status : Valid

Issue Date : 2023-06-30

Type : Chemical

Substance Number : 2217

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R0-CEP 2019-001 - Rev 00

Status : Valid

Issue Date : 2021-04-01

Type : Chemical

Substance Number : 2217

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Certificate Number : R1-CEP 2011-044 - Rev 01

Status : Withdrawn by Holder

Issue Date : 2017-10-25

Type : Chemical

Substance Number : 2217

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine Ph. Eur

Date of Issue : 2023-12-26

Valid Till : 2026-12-03

Written Confirmation Number : WC-0487

Address of the Firm : Plot No. 48-50, 209-211, IDA, Phase-ll, Pashamylaram, Patancheru, Sangareddy Dis...

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine Crystalline Polymorph Form II Ph.Eur

Date of Issue : 2025-07-11

Valid Till : 2028-06-25

Written Confirmation Number : WC-0023

Address of the Firm : Sy. No\'s. 52,53,58,59,61 to 78, 127 & 128, Pydibhimavaram Village & Sy. No\'s. ...

blank

03

Cipla

India
AACR Annual meeting
Not Confirmed
arrow

Cipla

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine BP/USP/PH. Eur

Date of Issue : 2025-06-20

Valid Till : 2028-07-02

Written Confirmation Number : WC-0140

Address of the Firm : D-22, M.I.D.C, Industrial Area,Kurkumbh, Taluka

blank

04

Hetero Drugs

India
AACR Annual meeting
Not Confirmed
arrow

Hetero Drugs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine BP/USP/Ph. Eur.

Date of Issue : 2025-09-03

Valid Till : 2028-08-08

Written Confirmation Number : WC-0041

Address of the Firm : Unit-I, Sy. No. 10, I.D.A, Gaddapotharam (V), Jinnaram (M), Sangareddy District,...

blank

05

Hetero Drugs

India
AACR Annual meeting
Not Confirmed
arrow

Hetero Drugs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine USP/Ph. Eur

Date of Issue : 2022-09-30

Valid Till : 2025-08-15

Written Confirmation Number : WC-0065

Address of the Firm : Unit-IX, Plot No. 2, Hetero Infrastructure- SEZ Ltd., N. Narasapuram (Village), ...

blank

06

Laurus Labs

India
AACR Annual meeting
Not Confirmed
arrow

Laurus Labs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine USP/EP/JP/Ph.Int.

Date of Issue : 2025-12-24

Valid Till : 2028-11-27

Written Confirmation Number : WC-0459

Address of the Firm : Plot No. 25, 25A to 25K, Atchutapuram, Rambilli (M), Visakhapatnam-531011, Andhr...

blank

07

Laurus Labs

India
AACR Annual meeting
Not Confirmed
arrow

Laurus Labs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine Ph.Eur/Ph.int/USP/IH

Date of Issue : 2024-08-04

Valid Till : 2026-03-22

Written Confirmation Number : WC-0395

Address of the Firm : Plot No. 18, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District ...

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine USP/EP

Date of Issue : 2025-09-29

Valid Till : 2028-09-28

Written Confirmation Number : WC-0118

Address of the Firm : Unit-1, Survey No. 10, Gaddapotharam (V), Kazipally Industrial Area, Jinnaram (M...

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine Ph. Eur

Date of Issue : 2025-09-29

Valid Till : 2028-09-28

Written Confirmation Number : WC-0189

Address of the Firm : Unit-2, Survey No.10 & 42, Gaddapotharam(V), Kazipally Industrial Area, Jinnaram...

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine IP/USP

Date of Issue : 2026-01-12

Valid Till : 2026-05-14

Written Confirmation Number : WC-0558

Address of the Firm : Plot No 28, Sy No 1,3,9,26, Thanam Village, Parawada Mandal, Parawada, Visakhapa...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 65862-259

Start Marketing Date : 2024-01-09

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 52482-003

Start Marketing Date : 2014-03-13

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 68554-0043

Start Marketing Date : 1995-11-17

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 42385-714

Start Marketing Date : 2017-07-07

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 55773-0589

Start Marketing Date : 2010-10-26

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 84206-0054

Start Marketing Date : 2024-09-06

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 84206-0055

Start Marketing Date : 2024-09-06

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 50787-0027

Start Marketing Date : 2009-07-08

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 67835-0017

Start Marketing Date : 2019-11-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

LAMIVUDINE

NDC Package Code : 70159-001

Start Marketing Date : 2016-02-02

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Lamivudine

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

02

HRV Pharma

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Lamivudine

About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...

HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing, manufacturing, and supply services to support partners entering new markets worldwide. HRV Pharma works closely with major pharma and food additive companies and represents over 30 Indian drugmakers, primarily serving Europe, the US, and the Middle East. Headquartered in India, it operates offices in the US, Switzerland, Dubai, Lithuania, and Turkey. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
HRV Global Life Sciences

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Anhui Biochem Pharmaceutical Co., Ltd. is a high tech enterprise which has integrated R&D, production and marketing specializing in synthetic technology of chiral compounds. We has...

Anhui Biochem Pharmaceutical Co., Ltd. is a high tech enterprise which has integrated R&D, production and marketing specializing in synthetic technology of chiral compounds. We has complete industry chain from API to FPPs products. We also have the largest, most complete line of anti-AIDS&HBV API Production facilities. The API products include Lamivudine USP, Zidovudine USP, Ritonavir USP, lopinavir, Nevirapine USP, Tenofovir Disoproxil Fumarate, Entecavir, NGF(Mouse Nerve Growth Factor), Capecitabine and other intermediates. The FPPs products include Lamivudine Tablet(100mg/150mg/300mg)
blank

04

Anwita Drugs

India
AACR Annual meeting
Not Confirmed
arrow

Anwita Drugs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Anwita Drugs is a technocrat-driven pharmaceutical company with over 28 years of expertise in designing and developing solid oral dosage forms (OSD), nutraceuticals, and dietary su...

Anwita Drugs is a technocrat-driven pharmaceutical company with over 28 years of expertise in designing and developing solid oral dosage forms (OSD), nutraceuticals, and dietary supplements. We specialize in the design, development, and optimization of solid, semi-solid, and liquid applications using cutting-edge technology. With strong R&D capabilities and a focus on niche product manufacturing, we deliver cost-effective, high-quality solutions. Our mission is to provide integrated, efficient services across multi-therapeutic domains.
blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Since 2004, Arene Lifesciences Private Limited is committed to a cause to deliver the best and to aim for continuous improvement in order to transform new knowledge into innovative...

Since 2004, Arene Lifesciences Private Limited is committed to a cause to deliver the best and to aim for continuous improvement in order to transform new knowledge into innovative synthetic processes, designed to ensure quality, efficiency and sustainability. Our leaders step outside to do things that symbolize our vision “to be recognized as a one of the leading Global manufacturers of Quality API and their intermediates”.Our expert teams maintain the highest global standards of quality and regulatory compliance, while our unparalleled customer support and attention will help our customers to maintain a competitive edge in the market.
blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGM...

Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGMP factory in 1986. JEIL's fine chemical production facilities are entirely controlled by the BGMP according to the GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals.On the other hands, JEIL is manufacturing FDF Products sold to Japan and other countries.With marketing strategy of 'First generic' and Innovative drug, JEIL have been extended the market in world-wide.
blank

08

Laurus Labs

India
AACR Annual meeting
Not Confirmed
arrow

Laurus Labs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Ph...

Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Out of Ten largest generic pharmaceutical companies in the world, by revenues, are our customers.
blank

09

Symed Labs

India
AACR Annual meeting
Not Confirmed
arrow

Symed Labs

India
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemist...

Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemistry related services. We are more than 300 employees strong and our core competence is in the application of strong process chemistry to manufacturing in a regulatory environment. For the past 15 years, Symed has been at the forefront of facilitating and accelerating drug development (and GMP manufacturing) of APIs. The company's technical and scientific teams provide reliable solutions and services to the global pharmaceutical industry.
blank

10

Viatris

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Viatris

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...

In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Lamivudine

Brand Name : Tenofovir Winthrop

Dosage Form : FCT

Dosage Strength : 150mg

Packaging : 30X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Sanofi

02

Lamivudine

Brand Name : Aspen Lamzid

Dosage Form : TAB

Dosage Strength : 150mg

Packaging : 60X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

03

Lamivudine

Brand Name : Aspen Lamivudine Syrup

Dosage Form : SOL

Dosage Strength : 10mg/ml

Packaging : 240X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

04

Lamivudine

Brand Name : Aspen Lamivudine 150 Mg

Dosage Form : TAB

Dosage Strength : 150mg

Packaging : 60X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

05

Lamivudine

Brand Name : Aspen Lamivudine 300Mg

Dosage Form : TAB

Dosage Strength : 300mg

Packaging : 30X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

06

Lamivudine

Brand Name : Virtrium 30/150/200

Dosage Form : TAB

Dosage Strength : 150mg

Packaging : 60X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

07

Lamivudine

Brand Name : Tenarenz

Dosage Form : TAB

Dosage Strength : 300mg

Packaging : 30X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

08

Lamivudine

Brand Name : Vulante

Dosage Form : FCT

Dosage Strength : 300mg

Packaging : 30X1mg

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

09

LAMIVUDINE

Brand Name : LAMIVUDINE

Dosage Form : TABLET;ORAL

Dosage Strength : 150MG

Packaging :

Approval Date : 2016-11-21

Application Number : 203586

Regulatory Info : DISCN

Registration Country : USA

Breckenridge Pharmaceutical

10

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lamivudine

Brand Name : Lamivudine

Dosage Form : Tablet

Dosage Strength : 100MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Octavius Pharma
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Accord Healthcare Slu

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Accord Healthcare Slu

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Lamivudine; Zidovudine

Brand Name : Lamivudina/Zidovudina Accord

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG; 300 MG

Packaging :

Approval Date : 20-01-2014

Application Number : 77815

Regulatory Info : Cancelled

Registration Country : Spain

blank

02

Accord Healthcare Bv

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Accord Healthcare Bv

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Abacavir; Lamivudine

Brand Name : Abacavir/Lamivudine Accord

Dosage Form : Film Coated Tablet

Dosage Strength : 600mg;300mg

Packaging :

Approval Date : 31-03-2016

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Zidovudine; Lamivudine

Brand Name : Lamivudine/Zidovudine Aurobindo

Dosage Form : Film Coated Tablet

Dosage Strength : 300MG; 150MG

Packaging :

Approval Date : 2013-02-20

Application Number :

Regulatory Info : Withdrawn

Registration Country : Malta

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

Brand Name : Zeffix

Dosage Form : Film Coated Tablet

Dosage Strength : 100MG

Packaging :

Approval Date : 11-01-2000

Application Number : 99114001

Regulatory Info : Authorized

Registration Country : Spain

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

Brand Name : Lamivudina Normon

Dosage Form : Film Coated Tablet

Dosage Strength : 100MG

Packaging :

Approval Date : 10-05-2012

Application Number : 75887

Regulatory Info : Authorized

Registration Country : Spain

blank

06

Mepha Pharma Ag

Switzerland
AACR Annual meeting
Not Confirmed
arrow

Mepha Pharma Ag

Switzerland
arrow
AACR Annual meeting
Not Confirmed

Abacavir; Lamivudine

Brand Name : Abacavir-Lamivudin-Mepha mg

Dosage Form : Film Coated Tablet

Dosage Strength : 600mg;300mg

Packaging :

Approval Date : 2018-07-04

Application Number : 67064

Regulatory Info : Allowed

Registration Country : Switzerland

blank

07

Mepha Pharma Ag

Switzerland
AACR Annual meeting
Not Confirmed
arrow

Mepha Pharma Ag

Switzerland
arrow
AACR Annual meeting
Not Confirmed

Lamivudine

Brand Name : Lamivudin-Mepha

Dosage Form : Film Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date : 05/08/2010

Application Number : 60516

Regulatory Info : Allowed

Registration Country : Switzerland

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Doravirine; Lamivudine; Tenofovir disoproxil fumarate

Brand Name : Delstrigo

Dosage Form : Film Coated Tablet

Dosage Strength : 100mg; 300mg; 245mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

09

Sandoz A/S

Switzerland
AACR Annual meeting
Not Confirmed
arrow

Sandoz A/S

Switzerland
arrow
AACR Annual meeting
Not Confirmed

Abacavir Hydrochloride Monohydrate; Lamivudine

Brand Name : Abacavir/Lamivudine Sandoz

Dosage Form : Film Coated Tablet

Dosage Strength : 600mg;300mg

Packaging :

Approval Date : 11-08-2016

Application Number : 2.01E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

10

Teva Bv

Israel
AACR Annual meeting
Not Confirmed
arrow

Teva Bv

Israel
arrow
AACR Annual meeting
Not Confirmed

Lamivudin; Zidovudin

Brand Name : Lamivudine/Zidovudine Teva

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg;300mg

Packaging :

Approval Date : 28-02-2011

Application Number : 2.01E+13

Regulatory Info : Deregistered

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 600MG BASE;EQ 50MG ...DOSAGE - TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG

USFDA APPLICATION NUMBER - 205551

read-more

DOSAGE - TABLET;ORAL - 150MG;200MG;300MG

USFDA APPLICATION NUMBER - 205626

read-more

DOSAGE - TABLET;ORAL - 150MG

USFDA APPLICATION NUMBER - 20564

read-more

DOSAGE - TABLET;ORAL - 300MG

USFDA APPLICATION NUMBER - 20564

read-more

DOSAGE - TABLET;ORAL - 100MG;300MG;300MG

USFDA APPLICATION NUMBER - 210807

read-more

DOSAGE - TABLET;ORAL - 300MG;300MG

USFDA APPLICATION NUMBER - 211284

read-more

DOSAGE - TABLET;ORAL - EQ 600MG BASE;300MG **...DOSAGE - TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 21652

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Co-Processed Excipients

read-more
read-more

Lubricants & Glidants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Empty Capsules

read-more
read-more

Rheology Modifiers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 134678-17-4 / Lamivudine API manufacturers, exporters & distributors?

Lamivudine manufacturers, exporters & distributors 1

57

PharmaCompass offers a list of Lamivudine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lamivudine manufacturer or Lamivudine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lamivudine manufacturer or Lamivudine supplier.

API | Excipient name

Lamivudine

Synonyms

134678-17-4, Epivir, Zeffix, Heptovir, Epivir-hbv, 136891-12-8

Cas Number

134678-17-4

Unique Ingredient Identifier (UNII)

2T8Q726O95

About Lamivudine

A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Lamivudine Manufacturers

A Lamivudine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lamivudine, including repackagers and relabelers. The FDA regulates Lamivudine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lamivudine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Lamivudine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Lamivudine Suppliers

A Lamivudine supplier is an individual or a company that provides Lamivudine active pharmaceutical ingredient (API) or Lamivudine finished formulations upon request. The Lamivudine suppliers may include Lamivudine API manufacturers, exporters, distributors and traders.

click here to find a list of Lamivudine suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Lamivudine USDMF

A Lamivudine DMF (Drug Master File) is a document detailing the whole manufacturing process of Lamivudine active pharmaceutical ingredient (API) in detail. Different forms of Lamivudine DMFs exist exist since differing nations have different regulations, such as Lamivudine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Lamivudine DMF submitted to regulatory agencies in the US is known as a USDMF. Lamivudine USDMF includes data on Lamivudine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lamivudine USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Lamivudine suppliers with USDMF on PharmaCompass.

Lamivudine JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Lamivudine Drug Master File in Japan (Lamivudine JDMF) empowers Lamivudine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Lamivudine JDMF during the approval evaluation for pharmaceutical products. At the time of Lamivudine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Lamivudine suppliers with JDMF on PharmaCompass.

Lamivudine KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Lamivudine Drug Master File in Korea (Lamivudine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lamivudine. The MFDS reviews the Lamivudine KDMF as part of the drug registration process and uses the information provided in the Lamivudine KDMF to evaluate the safety and efficacy of the drug.

After submitting a Lamivudine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lamivudine API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Lamivudine suppliers with KDMF on PharmaCompass.

Lamivudine CEP

A Lamivudine CEP of the European Pharmacopoeia monograph is often referred to as a Lamivudine Certificate of Suitability (COS). The purpose of a Lamivudine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lamivudine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lamivudine to their clients by showing that a Lamivudine CEP has been issued for it. The manufacturer submits a Lamivudine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lamivudine CEP holder for the record. Additionally, the data presented in the Lamivudine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lamivudine DMF.

A Lamivudine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lamivudine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Lamivudine suppliers with CEP (COS) on PharmaCompass.

Lamivudine WC

A Lamivudine written confirmation (Lamivudine WC) is an official document issued by a regulatory agency to a Lamivudine manufacturer, verifying that the manufacturing facility of a Lamivudine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lamivudine APIs or Lamivudine finished pharmaceutical products to another nation, regulatory agencies frequently require a Lamivudine WC (written confirmation) as part of the regulatory process.

click here to find a list of Lamivudine suppliers with Written Confirmation (WC) on PharmaCompass.

Lamivudine NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lamivudine as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Lamivudine API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Lamivudine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Lamivudine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lamivudine NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Lamivudine suppliers with NDC on PharmaCompass.

Lamivudine GMP

Lamivudine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lamivudine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lamivudine GMP manufacturer or Lamivudine GMP API supplier for your needs.

Lamivudine CoA

A Lamivudine CoA (Certificate of Analysis) is a formal document that attests to Lamivudine's compliance with Lamivudine specifications and serves as a tool for batch-level quality control.

Lamivudine CoA mostly includes findings from lab analyses of a specific batch. For each Lamivudine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lamivudine may be tested according to a variety of international standards, such as European Pharmacopoeia (Lamivudine EP), Lamivudine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lamivudine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty